InMode Ltd. (NASDAQ:INMD) Shares Sold by Marco Investment Management LLC

Marco Investment Management LLC lowered its stake in InMode Ltd. (NASDAQ:INMD) by 4.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 35,975 shares of the healthcare company’s stock after selling 1,600 shares during the quarter. Marco Investment Management LLC’s holdings in InMode were worth $610,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of INMD. Doma Perpetual Capital Management LLC grew its holdings in shares of InMode by 210.7% during the second quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock worth $36,685,000 after buying an additional 1,363,841 shares in the last quarter. Swedbank AB purchased a new stake in InMode in the 1st quarter worth approximately $17,634,000. Federated Hermes Inc. grew its stake in InMode by 191.9% in the 2nd quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock worth $20,520,000 after acquiring an additional 739,629 shares during the period. Acadian Asset Management LLC raised its holdings in InMode by 63.6% in the 2nd quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock valued at $20,502,000 after acquiring an additional 437,122 shares during the last quarter. Finally, Lombard Odier Asset Management Europe Ltd purchased a new position in shares of InMode during the 2nd quarter worth $4,104,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on INMD. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research report on Thursday, October 31st. BTIG Research initiated coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target for the company. Finally, Barclays cut their price objective on shares of InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $22.60.

InMode Trading Up 2.9 %

Shares of InMode stock opened at $19.02 on Friday. The business’s fifty day moving average price is $17.40 and its 200 day moving average price is $17.46. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80. The stock has a market capitalization of $1.60 billion, a P/E ratio of 10.28 and a beta of 2.15.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.